A study published in Ophthalmologica by researchers from the Hospital de São João, Porto in Portugal has looked at the effect of dorzolamide versus ketorolac eye drops on macular edema in patients with Retinitis Pigmentosa (RP) and Usher's syndrome (US).
A total of 28 eyes of 18 patients (5 eyes had US, 23 had RP) were studied, with 15 eyes allocated to ketorolac tromethamine 0.5% (4 drops daily regimen), while 13 eyes to dorzolamide hydrochloride 2% (3 drops daily regimen) treatment groups.
Snellen's best-corrected visual acuity (BCVA), foveal thickness (FT) and foveal zone thickness (FZT) measured by Stratus® optical coherence tomography (OCT) were evaluated at baseline, 1, 3, 6 and 12 months after treatment.
Patients assigned to ketorolac had a baseline BCVA of 0.37 ± 0.17 logMAR which improved at the end of 1 year to 0.28 ± 0.16 (p = 0.02). Three eyes (20%) of 2 patients improved by 7 letters or more. Mean FT and FZT did not change significantly during the study follow-up. After 1 year of treatment, 4 eyes (27%) of 3 patients showed an improvement of at least 16% of FT and 11% of FZT. Patients assigned to dorzolamide had a baseline BCVA of 0.48 ± 0.34 logMAR which improved in the first 6 months (0.40 ± 0.30; p = 0.01), with a decrease at 1 year (0.42 ± 0.27; p = 0.20). Seven eyes (54%) of 5 patients had an improvement of 7 letters or more. Mean FT and FZT did not change significantly either. After 1 year of treatment, 3 eyes (23%) of 2 patients showed an improvement of at least 16% on FT and 11% on FZT.
The researchers suggest that dorzolamide and ketorolac improves visual acuity in selected cases.
Retina India is a not-for-profit organization, registered with the Charity Commissioner, Mumbai, India, established for empowering people with retinal disorders, and bringing them and their families on a common platform with physicians, researchers, counselors, low vision and mobility experts and other specialists.
No comments:
Post a Comment